JSW Motors, KPIT partner to build software, digital backbone for new energy vehicles portfolio
JSW Motors, the newly-launched automotive business vertical of the JSW Group, is investing USD 3 billion over the next five years to develop and manufacture electric, hybrid, and plug-in hybrid vehicles in India. The company's first New Energy Vehicle (NEV) is set to debut on the Indian roads in the second half of FY2026. With a 630-acre automotive hub under development in Bidkin, Maharashtra, JSW Motors is combining global standards with local relevance to drive high-performance, sustainable vehicles to Indian consumers, the release added. The JSW Motors and KPIT Technologies' partnership aims to leverage the latter's expertise in software and systems development (of over two decades across more than 2,000 global vehicle production programmes, including multiple Software Defined Vehicle programmes) and will strengthen JSW Motors' vision to disrupt the domestic automotive market through innovation and global collaboration.
The companies did not divulge the size of the deal. KPIT management during the company's earnings call on Wednesday said the partnership is initially for three years, and revenue will start flowing in from the next quarter onwards. According to the release, the partnership underscores KPIT's strategic commitment to the Indian market and, along with JSW, "promises to deliver superlative customer experiences and accelerate India's transition to clean mobility". Kishor Patil, CEO and MD of KPIT Technologies, said: "KPIT is proud to partner with JSW Motors in their ambitious journey to transform India's automotive landscape. Our experience across global vehicle programmes and SDV positions us uniquely to contribute to JSW's vision". This partnership reflects strategic focus on the Indian market and shared commitment to delivering cutting-edge technology that enhances customer experiences and accelerates clean mobility, he said. "The partnership will include KPIT bringing advanced competencies in electric propulsion systems, battery innovation, and SDV architectures that enable continuous feature upgrades and superior consumer experiences," Patil informed. Ranjan Nayak, CEO of JSW Motors, said: "We plan to build world-class automotive products in India by integrating the best of technologies from across the globe. KPIT's expertise in software and systems development is a cornerstone of our strategy to deliver best-in-class, technologically-advanced, high-performance, and sustainable vehicles."
Together, the two sides aim to energise the Indian auto ecosystem and set new benchmarks for innovation and customer satisfaction, Nayak added. PTI
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
10 minutes ago
- Business Standard
US tariffs should not be cause for disengaging from trade talks, blocs
The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —
&w=3840&q=100)
Business Standard
10 minutes ago
- Business Standard
Collaboration for future: Isro and India will benefit from Nasa
Artemis signup allows Isro and the fast-growing Indian aerospace sector to bid for Nasa tenders and the famously frugal Indian engineering sector could find opportunities there and pick up new skills Business Standard Editorial Comment Mumbai Listen to This Article The successful launch of the Nisar (Nasa-Isro Synthetic Aperture Radar) satellite from the Satish Dhawan Space Centre marks the second big mission where the two space agencies have joined hands, coming soon after gaganaut Shubhanshu Shukla travelled to the International Space Station on the Axiom 4 mission. This may be the precursor to more cooperation between the agencies, given that India in 2023 signed up for the Artemis Accords. The Artemis Accords provide a common set of principles for civil exploration and use of outer space. While both agencies benefit from cooperation, the Indian Space Research Organisation (Isro) may benefit
India Today
26 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch
